MARTINSRIED/MUNICH, Germany, May 29 /PRNewswire-FirstCall/ --
PRINCETON, N.J. -- GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX
index; Nasdaq: GPCB) today announced that the Company will host an investor
event on Monday, June 4, 2007, 6:00-7:30 pm Central Time (June 5, 2007 at 1
am CEST) during the ASCO Conference in Chicago, IL. The event will be
webcast live and will be accessible through the GPC Biotech Web site at
http://www.gpc-biotech.com. A replay will also be available via the Web
site.
Cora Sternberg, M.D., FACP, Chief of the Department of Medical Oncology
at the San Camillo and Forlanini Hospitals, Rome, Italy is a confirmed
guest speaker for the event and will discuss the investigational drug,
satraplatin as well as lead a general discussion regarding the treatment of
hormone- refractory prostate cancer. Dr. Sternberg is a leading authority
in the treatment of genitourinary cancers and one of the principal
investigators of the SPARC registrational trial. Dr. Sternberg will give a
podium presentation on data from the SPARC trial at the ASCO Annual Meeting
Members of the GPC Biotech senior management team will also be
available to discuss corporate activities.
About GPC Biotech
GPC Biotech AG is a publicly traded biopharmaceutical company focused
on discovering, developing and commercializing new anticancer drugs. GPC
Biotech's lead product candidate satraplatin is currently under review by
the U.S. FDA for hormone-refractory prostate cancer patients whose prior
chemotherapy has failed. Satraplatin was in-licensed from Spectrum
Pharmaceuticals, Inc. GPC Biotech is also developing a monoclonal antibody
with a novel mechanism-of-action against a variety of lymphoid tumors,
currently in Phase 1 clinical development, and has ongoing drug development
and discovery programs that leverage its expertise in kinase inhibitors.
GPC Biotech AG is headquartered in Martinsried/Munich (Germany), and has a
wholly owned U.S. subsidiary headquartered in Princeton, New Jersey. For
additional information, please visit GPC Biotech's Web site at
http://www.gpc-biotech.com.
This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of GPC Biotech AG,
including statements about the status of the FDA review process. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause
future results, performance or achievements to differ significantly from
the results, performance or achievements expressed or implied by such
forward-looking statements. Actual results could differ materially
depending on a number of factors, and we caution investors not to place
undue reliance on the forward- looking statements contained in this press
release. In particular, there can be no guarantee that additional
information relating to the safety, efficacy or tolerability of satraplatin
may be discovered upon further analysis of data from the SPARC trial or
analysis of additional data from other ongoing clinical trials for
satraplatin. Furthermore, we cannot guarantee that satraplatin will be
approved for marketing in a timely manner, if at all, by regulatory
authorities nor that, if marketed, satraplatin will be a successful
commercial product. We direct you to GPC Biotech's Annual Report on Form
20-F for the fiscal year ended December 31, 2005 and other reports filed
with the U.S. Securities and Exchange Commission for additional details on
the important factors that may affect the future results, performance and
achievements of GPC Biotech. Forward-looking statements speak only as of
the date on which they are made and GPC Biotech undertakes no obligation to
update these forward-looking statements, even if new information becomes
available in the future.
Satraplatin has not yet been approved by the FDA in the U.S., the EMEA
in Europe or any other regulatory authority and no conclusions can or
should be drawn regarding its safety or effectiveness. Only the relevant
regulatory authorities can determine whether satraplatin is safe and
effective for the use(s) being investigated.
SOURCE GPC Biotech AG
 back to top
Related links:
http://www.gpc-biotech.com/
CONTACT:
Martin Braendle Director, Investor Relations
& Corporate Communications, +49-(0)89-8565-2693,
ir@gpc-biotech.com, or In the U.S., Laurie Doyle Director,
Investor Relations & Corporate Communications, +1-609-524-5884,
usinvestors@gpc-biotech.com, both of GPC Biotech AG
|
